Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

@article{Malempati2012PhaseIT,
  title={Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.},
  author={Suman Malempati and Brenda Weigel and Ashish Mark Ingle and Charlotte Hsieh Ahern and Julie M Carroll and Charles Roberts and Joel M. Reid and Stephen C. Schmechel and Stephan D. Voss and Steven Y Cho and Helen Chen and Mark D. Krailo and Peter C. Adamson and Susan M. Blaney},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 3},
  pages={256-62}
}
PURPOSE A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity in Ewing sarcoma (ES). PATIENTS AND METHODS Pediatric patients with relapsed or refractory solid tumors were treated with cixutumumab as a 1-hour intravenous infusion once per week. Two dose levels-6… CONTINUE READING